Single Arm Phase II Clinical Trial

Haitao Pan () and Ying Yuan ()
Additional contact information
Haitao Pan: St. Jude Children’s Research Hospital, Department of Biostatistics
Ying Yuan: The University of Texas MD Anderson Cancer Center, Department of Biostatistics

Chapter Chapter 6 in Bayesian Adaptive Design for Immunotherapy and Targeted Therapy, 2023, pp 91-118 from Springer

Abstract: Abstract Single-arm phase II trials are common in cancer research and provide a useful approach to screen and identify promising treatments that warrant phase III trials, using small sample sizes. This chapter first presents Simon’s two-stage design; and then introduces several novel Bayesian designs, including posterior probability (PrP) and predictive probability (PreP) approaches, and Bayesian optimal Phase II design (BOP2) and its extensions. Bayesian designs, particularly BOP2, provide a highly flexible and efficient approach to addressing the complexity of immunotherapies and targeted therapies; such as ordinal endpoints, multiple endpoints, co-primary endpoints, and multiple interim analyses.

Date: 2023
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-981-19-8176-0_6

Ordering information: This item can be ordered from
http://www.springer.com/9789811981760

DOI: 10.1007/978-981-19-8176-0_6

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().